Revisiting Chemo in EGFR-Mutant NSCLC
*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials. A phase III trial from India showed that median PFS increased from 8 months with the EGFR inhibitor gefitinib (Iressa) to 16 months with gefitinib plus chemotherapy.